Abstract
The recently approved combination of meropenem and vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae We evaluated the efficacy of meropenem-vaborbactam against three clinically relevant isolates in a murine pyelonephritis model. The data indicate that the combination of meropenem and vaborbactam significantly increased bacterial killing compared to that with the untreated controls. These data suggest that this combination may have utility in the treatment of complicated urinary tract infections due to KPC-producing, carbapenem-resistant Enterobacteriaceae.
Keywords:
KPC; Klebsiella pneumoniae carbapenemase; meropenem; pyelonephritis; vaborbactam.
Copyright © 2017 American Society for Microbiology.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Anti-Bacterial Agents / therapeutic use*
-
Bacterial Proteins / metabolism
-
Boronic Acids / therapeutic use*
-
Carbapenem-Resistant Enterobacteriaceae / drug effects*
-
Carbapenem-Resistant Enterobacteriaceae / isolation & purification
-
Disease Models, Animal
-
Drug Combinations
-
Escherichia coli / drug effects*
-
Humans
-
Klebsiella pneumoniae / drug effects*
-
Klebsiella pneumoniae / isolation & purification
-
Klebsiella pneumoniae / metabolism
-
Meropenem / therapeutic use*
-
Mice
-
Microbial Sensitivity Tests
-
Pyelonephritis / drug therapy*
-
Pyelonephritis / microbiology
-
Urinary Tract Infections / drug therapy*
-
Urinary Tract Infections / microbiology
-
beta-Lactamase Inhibitors / therapeutic use*
-
beta-Lactamases / metabolism
Substances
-
Anti-Bacterial Agents
-
Bacterial Proteins
-
Boronic Acids
-
Drug Combinations
-
beta-Lactamase Inhibitors
-
vaborbactam
-
beta-Lactamases
-
carbapenemase
-
Meropenem